The cas nuclease global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Cas Nuclease Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size –
The Cas nuclease market size has grown rapidly in recent years. It will grow from $2.75 billion in 2023 to $3.27 billion in 2024 at a compound annual growth rate (CAGR) of 18.9%. The growth in the historic period can be attributed to rising genome editing, increasing biotechnology research funding, demand for personalized medicine, government support for genetic research, and the growing prevalence of genetic disorders.
The Cas nuclease market size is expected to see rapid growth in the next few years. It will grow to $6.56 billion in 2028 at a compound annual growth rate (CAGR) of 19.0%. The growth in the forecast period can be attributed to increasing investment in gene editing startups, rising demand for therapeutic genome editing, regulatory approvals for gene therapies, development of Cas-based diagnostics, and growing interest in epigenome editing. Major trends in the forecast period include the adoption of CRISPR for rare disease treatment, growth in agricultural gene editing, rising interest in synthetic RNA-guided nucleases, development of CRISPR-based drug discovery, and rise of ethical debates around genome editing.
Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/cas-nuclease-global-market-report
Scope Of Cas Nuclease Market
The Business Research Company’s reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Cas Nuclease Market Overview
Market Drivers –
The increasing investment in biotechnology is expected to propel the growth of the Cas nuclease market going forward. The surge in investment in biotechnology is fueled by breakthroughs in scientific research, rising demand for advanced medical treatments, the expanding applications of biotechnology across industries, and the promising economic potential of innovations and technologies. Biotechnology investment in Cas nucleases accelerates advancements in gene-editing technologies for medical, agricultural, and research applications. For instance, in August 2024, according to data published by the UK Bioindustry Association (BIA), a UK-based trade association for innovative life sciences and biotech industry, the UK’s life sciences and biotech sector raised $2.61 billion in the first half of 2024, surpassing the $2.38 billion raised in all of 2023. Therefore, the increasing investment in biotechnology is driving the Cas nuclease market.
Market Trends –
Major companies operating in the Cas nuclease market are focusing on developing advanced technology solutions, such as CRISPR-based gene editing therapy, to sustain their position in the market. CRISPR-based gene editing therapy is a medical approach that uses the CRISPR-Cas9 system to precisely modify deoxyribonucleic acid (DNA) sequences in living organisms to treat genetic disorders by correcting mutations at the molecular level. For instance, in November 2023, Vertex Pharmaceuticals Incorporated, a US-based biotechnology company, and CRISPR Therapeutics, a Switzerland-based gene editing company, announced the authorization of CASGEVY (exagamglogene autotemcel) by the UK Medicines and Healthcare Products Regulatory Agency (MHRA). This marks a significant milestone as it is the first-ever gene therapy utilizing CRISPR/Cas9 technology, approved for treating sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in patients aged 12 and older.
The cas nuclease market covered in this report is segmented –
1) By Type: Cas9, Cas12, Cas13, Other Cas Nucleases
2) By Delivery Method: Viral Vectors, Lipid Nanoparticles, Electroporation, Microinjection, Transposons
3) By Distribution Channel: Direct Sales, Distributor
4) By Application: Gene Editing Cell Line Construction, Animal Models, Bioagriculture, Gene Therapy, Other Applications
5) By End-User: Academic And Government Research Institutions, Biotechnology And Pharmaceutical Companies, Contract Research Organizations (CROS), Agricultural Biotechnology Companies, Other End-Users
Get an inside scoop of the cas nuclease market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=18987&type=smp
Regional Insights –
North America was the largest region in the Cas nuclease market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cas nuclease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Key Companies –
Major companies operating in the cas nuclease market are Thermo Fisher Scientific Inc., AstraZeneca PLC, Merck KGaA, Vertex Pharmaceuticals, Agilent Technologies Inc., Bio-Rad Laboratories Inc., Promega Corporation, GenScript Biotech Corporation, CRISPR Therapeutics AG, Integrated DNA Technologies Inc., Takara Bio Inc., New England Biolabs Inc., Horizon Discovery Group plc, OriGene Technologies Inc., Applied Biological Materials Inc. (ABM), Synthego Corporation, Novoprotein Scientific Inc., genOway, Precision BioSciences, Editas Medicine, Creative Biolabs, Cellectis, Caribou Biosciences, Addgene
Table of Contents
1. Executive Summary
2. Cas Nuclease Market Report Structure
3. Cas Nuclease Market Trends And Strategies
4. Cas Nuclease Market – Macro Economic Scenario
5. Cas Nuclease Market Size And Growth
…..
27. Cas Nuclease Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
